Part 2: Inflammatory Disease IL-13, IL-17, IL-12/23, IL-23, IL-31, IL-36, JAKi

Adbry

tralokinumab

AD

Indication for tralokinumab (Adbry)

600 mg initially then 300 mg q other week

Adult dosing for Adbry

ocular ades

Adbry has some common _____ ___

1 inch

Adbry: administer doses in one body area at least _ ___ apart from

Treat helminth infections

you must _____ ____ _____ prior to starting Adbry

IL-13

Adbry is an ____ Inhibitor

IL-13

Ebglyss is an ___ inhibitor

AD

Indication for Ebglyss

500 mg week 0 and week 2, then 250 mg qow until week 16

adult and ped dosing for Ebglyss

Treat helminth infections

for Ebglyss, you must _____ ______ ____ prior to initiation

ocular ade

ebglyss has concerns for _____ ____

12, 40

Ebglyss is approved for ped patients > ___ weighing > ___

Exacerbations or new onset of IBD

concern with IL-17 inhibitors

4 days

Cosentyx is stable at rm temp for __ ____

HS, PP (adult and ped), PsA(adult and ped) , AS, nr-axSpA, enthesis-related arthritis (ped),

indications for Secukinumab (Cosentyx)

150 mg pen, PFS, 75 mg PFS

formulations for cosentyx

impetigo, inc LFT, neutropenia, IBD

rare ADE for Cosentyx

300 mg q week x 5 weeks, then 300 mg q 4 weeks

HS and PP dosing Cosentyx

AS, PsA, PP(adult and peds), nr-axSpA,

indications for taltz

citrate free

taltz is ____ ___

neutropenia, IBD

rare ADE for taltz

80 mg Pen or PFS, 40 mg PFS, 20 mg PFS

formulations for taltz

PP dosing taltz

160 mg once, then 80 mg week 2, 4, 6, 8, 10 ,12 then 80 mg q 4 weeks

AS and PsA dosing taltz

160 mg once, then 80 mg q 4 weeks

PP, PsA, nr-axSpA, AS, HS

indications for bimzelx

suicidal ideation

side effect to watch for in patients taking bimzelx

320 mg week 0, 4, 8 ,12, and 16 then 320 mg q 8 weeks

PP dosing for bimzelx

320 mg q 2 weeks for 16 weeks then q 4 weeks after

HS dosing for bimzelx

siliq

broadalumab

PP

indications for siliq

IL-17

siliq is an ____ ___ inhibitor

REMS

Siliq has a ______ program for the risk of suicidal ideation side effect

serious infections ,eczema, CD (CI)

rare side effects for Siliq

Crohn’s disease

also a contraindication, patients on Siliq have to be monitored for new onset or hx of ______ _____

210 mg week 0, 1, 2 and then q 2 weeks

PP dosing siliq

12/23

ustekinumab is an _____ inhibitor

PP (adult and peds) , PsA (adults and peds), CD, UC

indications for stelara

BCG vaccine

____ _______ do not give for 1 year prior to during, or 1 year following d/c of treatment

RPLS

rare side effects of stelara

IV, SC

formulations for dosing of CD and UC

induction dosing (IV) for CD/UC

< 55kg: 260mg as a single dose

>55 kg to 85 kg: 390 mg as single dose

> 85 kg: 520mg as single dose

maintenance dosing of CD/UC (SC)

90 mg q 8 weeks begin 8 weeks after IV induction

Monitoring for IL-23 inhibitors

baseline:TB, s/sx of infection, avoid live vaccines

IL-23

tildrakizumab is an ____ inhibitor

ilumya

tildrakizumab

PP

indication for Ilumya

office administration only

Ilumya is for ___ ______ ___

dosing for ilumya

100 mg week 0, 4, and q 12 weeks thereafter

PsA, PP, CD, UC

indications for Skyrizi

liver enzymes, bilirubin

check ____ ____ and _____ before starting and during induction of Skyrizi

PsA and PP dosing for Skyrizi

150mg, at week 0, 4, and q 12 weeks thereafter

Tinea, HSV, cellulitis, osteomyelitis, sepsis

rare ADE for Skyrizi

gueslkumab

tremfya

100 mg SC week 0, 4, and q 8 weeks after

PsA and PP dosing for tremfya

one-press

tremfya is supplied as an ___ ____ controlled injector device

IL-23

mirikizumab is an ____ inhibitor

liver enzymes, bilirubin

baseline and during treatment of Omvoh monitor _______ and _______

mirikizumab

omvoh

loading dose for UC for omvoh

300 mg weeks 0,4, and 8

loading dose for CD for omvoh

900 mg weeks 0,4 and 8

IL-31

Nemluvio is an ____ inhibitor

AD, PN

indications for Nemluvio

nemolizumab

Nemluvio

dual chamber prefilled pen

nemluvio is provided as a ____ _____ ______ ______

LDD

Nemluvio is a ____

AD pediatric dosing for nemluvio

60mg once, followed by 30 mg q 4 weeks

8 week

for AD patients you can extend frequency of Nemluvio to _____ after 16 weeks for patients who achieve clear or almost clear skin

IL-36

spesolimab (Spevigo) is an ____ inhibitor

Generalized pustular psoriasis

indication for Spevigo

via IV

Spevigo: 900 mg once ___ ____ if flare persist, an additional 900 mg may be given one week later

after IV treatment

Spevigo: SC dose _____ ___ ______: 300 mg q 4 week initiated 4 weeks after IV dose

> 12 yo

Spevigo is approved for use for adults and pediatrics ___ ____ weighing at least 40 kg

HA, diarrhea, UTI, increased LFTs, HLD, URI

Common adverse drug effects for JAK i

anemia, hepatotoxicity, skin cancer, serious infections, HZV, diverticulitis

rare side effects of JAK inhibitors

malignancy, thrombosis, including DVT, PE, MACE, mortality

boxed warnings for JAKi

monitoring for JAKi

LFTS, CBCd, lipid panel

renal impairment, hepatic impairment, anemia, lymphopenia, neutropenia

reasons for dose reduction or d/c for JAKi

tofacitinib

xeljanz

RA, AS, PsA, JIA, UC

indications for xeljanz

RA, AA

indications for olumiant

baricitinib

olumiant

CYP3A4, 2C19

avoid use w/ strong _______ inducers or ______ inhibitors with Xeljanz

GI perforation

for xeljanz, caution in patients at increased risk for ____ _______

tablet shell

Xeljanz XRL inert _____ ____ in stool: caution in preexisting severe GI narrowing

9g/dL

Xeljanz: avoid in patient with Hb less than _____

RA, AA

indications for olumiant

OAT3, 8g/dl

Olumiant: avoid use with ______ inhibitors, and Hb less than ____

RA, PsA, AD, AS, nr-axSpA, GCA, JIA, UC, CD

indications for Upadacitinib (Rinvoq)

AD

indications for abrocitinib (Cibinqo)

GI perforation, 8g/dL

Rinvoq: caution in patients at increased risk of ___ ____ and Hb less than ___

12, 40

rinvoq: for AD indicated for ages ____ and older and > ____ kg

100 mg daily

Cibinqo dosing for AD

Ritlectinib

Litfulo

AA

indication for ritlectinib

deuroxolitinib

leqselvi

AA

indication for leqselvi

50 mg QD

litfulo AA dosing

CYP2C9

Leqselvi - prior to initiating therapy, determine _______ genotype; do not use Deuroxolitinib in ______ poor metabolizers

ruxolitinib

Opzelura